Treatment of severe lupus nephritis: the new horizon

@article{Chan2015TreatmentOS,
  title={Treatment of severe lupus nephritis: the new horizon},
  author={Tak Mao Chan},
  journal={Nature Reviews Nephrology},
  year={2015},
  volume={11},
  pages={46-61}
}
  • T. Chan
  • Published 2015
  • Medicine
  • Nature Reviews Nephrology
Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus, and an important cause of both acute kidney injury and end-stage renal disease. Despite its aggressive course, lupus nephritis is amenable to treatment in the majority of patients. The paradigm of immunosuppressive treatment for lupus nephritis has evolved over the past few decades from corticosteroids alone to corticosteroids combined with cyclophosphamide. Sequential treatment regimens using various agents… Expand
The safety of pharmacological treatment options for lupus nephritis
TLDR
The conventional and newer pharmacological options for managing LN focusing on drug safety and toxicity issues are discussed, with concerns remain about treatment toxicity especially long term glucocorticoid use and exposure to cumulative cyclophosphamide doses. Expand
Lupus Nephritis Clinical Trials: A Critical Appraisal
TLDR
Heterogeneity, unpredictability, and susceptibility to complicating diseases has hampered the conduct of LN randomized clinical trials, and several treatment regimens are now generally regarded as effective and reasonably safe for management of severe proliferative LN. Expand
Lupus nephritis: An approach to diagnosis and treatment in South Africa.
  • I. Okpechi, O. Ameh
  • Medicine
  • South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • 2015
TLDR
Treatment for LN patients with end-stage renal disease (class VI) need to be prepared for renal replacement therapy (dialysis and renal transplantation) and adjunctive therapies such as renin angiotensin aldosterone system blockade, bone protection, blood pressure control and chloroquine help to retard the progression of kidney disease. Expand
A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies
TLDR
Recent advances in the understanding of disease pathogenesis in lupus nephritis are discussed in the context of potential emerging therapies. Expand
What is damaging the kidney in lupus nephritis?
TLDR
Approaches based on a molecular–proteomic–lipidomic classification of disease should yield new information about the functional basis of disease heterogeneity so that the most effective and least toxic treatment regimens can be formulated for individual patients. Expand
Lupus Nephritis in Asia: Clinical Features and Management
TLDR
Treatment responses and clinical outcomes in Asian patients with LN compare favorably with patients from other parts of the world, and the 10-year renal outcome and renal survival rate appear to be better in Asians. Expand
[Unmet needs in systemic lupus erythematosus].
  • K. Ichinose
  • Medicine
  • Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology
  • 2017
TLDR
The unmet needs of diagnosis and treatment with SLE, especially those with LN and NPSLE, are summarized with data from the authors' own experiences. Expand
Update on Biologic Therapies for Systemic Lupus Erythematosus
TLDR
Although many investigational agents exhibited insufficient efficacy or inadequate safety in clinical trials, one of them, belimumab, fulfilled the efficacy and safety regulatory requirements and was approved for the treatment of SLE in Europe and the USA, which confirms that advances in this field are possible. Expand
Redefining lupus nephritis: clinical implications of pathophysiologic subtypes
TLDR
The heterogeneous mechanisms involved in the pathogenesis of lupus nephritis are discussed and how improved understanding of underlying disease mechanisms might help guide therapeutic strategies are discussed. Expand
The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.
TLDR
It is becoming clear that the immunologic features, and probable underlying mechanisms, are very different in lupus glomerulonephritis and TII at the time of biopsy, and defining these in situ immune mechanisms should lead to a better understanding of prognostically meaningful l upus nephritis subsets and show novel therapeutic opportunities. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 238 REFERENCES
Overview of lupus nephritis management guidelines and perspective from Asia
TLDR
This manuscript summarizes the discussions by the group and presents consensus views on the clinical management and treatment of adult Asian patients with LN, taking into account both the available evidence and expert opinion in areas where evidence remains to be sought. Expand
Lupus nephritis: lessons from murine models
TLDR
Analysis of the mechanisms of action of novel immunomodulatory drugs in multiple models of murine lupus clearly shows that interacting networks of immune and effector pathways are recruited as the disease progresses. Expand
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.
  • R. Pepper, M. Griffith, +5 authors T. Cairns
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2009
TLDR
This data demonstrates the efficacy of a rituximab and MMF based regime in the treatment of lupus nephritis, allowing a reduction or total withdrawal of corticosteroids. Expand
B-cell depletion in the treatment of lupus nephritis
TLDR
The current evidence on the use of B-cell depletion in the treatment of lupus nephritis is discussed, which is derived from case studies and clinical trials including a total of over 800 patients. Expand
Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?
TLDR
The pooled results suggest that mycophenolate mofetil and cyclophosphamide are equally effective in inducing remission of severe lupus nephritis, however, relapse rates and risk of developing ESRD were higher for mycopenolate m ofetil compared with cycloph phosphamide. Expand
Cyclophosphamide: new approaches for systemic lupus erythematosus
TLDR
This review will touch on the traditional intravenous ‘pulse’ cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cycloph phosphamide. Expand
Biological therapy for lupus nephritis—tribulations and trials
Several new targeted biologic agents for treating lupus nephritis are on the horizon; however, it is important to determine the circumstances in which they should be used, and how to optimallyExpand
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.
TLDR
It is concluded that, as compared with high-dose oral prednisone alone, treatment of lupus glomerulonephritis with intravenous cyclophosphamide reduces the risk of end-stage renal failure with few serious complications. Expand
Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis
TLDR
The results of extended follow-up and long-term effectiveness of these treatment regimens, as well as morbidity and mortality, in patients participating in this trial are reported. Expand
Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
TLDR
Addition of anti-CD20 treatment to conventional immunosuppressive therapy may be a beneficial strategy in refractory lupus nephritis and autoimmune cytopenias, possibly by reducing the levels of pathogenic autoantibodies. Expand
...
1
2
3
4
5
...